Anbio Biotechnology Class A (NNNN)
NASDAQ: NNNNHealthcareMedical Instruments & SuppliesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NNNN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $215.07M
- P/E (TTM)
- 32.67
- EPS (TTM)
- $0.15
- Dividend yield
- None
- 52-week range
- 4.66 – 44.73
- Day range
- 4.72 – 4.99
- Volume / Avg
- 36.75K / 148.96K
- Beta
- —
- Shares outstanding
- 43.89M
52-week range
NNNN stock today
Anbio Biotechnology (NNNN) closed at $4.90 on Oct 7, essentially unchanged from the prior close, versus the S&P 500's 0.22% decline. Trading was light, with 36.75K shares changing hands, about 25% of the average daily volume. At this level, NNNN sits near the bottom of its 52-week range of $4.66 to $44.73: 89.0% below the high, set on Dec 5, 2025 and 5.2% above the low.
NNNN is down 83.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 83.4%. At 32.7x trailing earnings, Anbio Biotechnology trades above the peer-group median of 13.3x.
Summary generated from market data by MetaCap's automated system. Methodology
About Anbio Biotechnology
Company profileAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- CEO
- Mr. Michael Lau M.B.A., Ph.D.
- Headquarters
- Frankfurt am Main
- Employees
- 27
- IPO year
- 2025
- Website
- anbiobiotechnology.com
Anbio Biotechnology peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PDEXPro-Dex Inc. | 62.80 | -3.27% | $201.17M | vs NNNN |
| UTMDUtah Medical Products Inc. | 73.45 | -0.51% | $233.12M | vs NNNN |
| OSUROraSure Technologies Inc. | 3.73 | -1.06% | $257.25M | vs NNNN |
| ZJYLJIN MEDICAL INTERNATIONAL LTD. Class A | 2.12 | +6.53% | $158.29M | vs NNNN |
| KRMDKORU Medical Systems Inc. | 2.98 | -0.67% | $136.88M | vs NNNN |
| SMTISanara MedTech Inc. | 35.05 | +0.14% | $322.04M | vs NNNN |
| EMBCEmbecta Corp. | 5.91 | -0.67% | $334.86M | vs NNNN |
| ANGOAngioDynamics Inc. | 14.19 | -1.59% | $596.75M | vs NNNN |
Indexes, lists and sector
Appears in lists
Anbio Biotechnology stock FAQ
What is Anbio Biotechnology's stock price today?
NNNN last traded at $4.90 as of Oct 7, 4:00 PM EDT, up 0.00% on the day. Prices are delayed at least 15 minutes.
What is NNNN's P/E ratio?
NNNN trades at a trailing P/E ratio of 32.67, compared with a median of 13.3 for its closest peers.
Who is Anbio Biotechnology's CEO?
Mr. Michael Lau M.B.A., Ph.D. is the chief executive officer of Anbio Biotechnology Class A, which has about 27 employees.
What is the NNNN 52-week high?
The 52-week high for NNNN is $44.73 and the 52-week low is $4.66. The stock is currently 89.0% below its high.